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Introduction
Feline herpesvirus type 1 (FHV-1), an enveloped, double-
stranded alphaherpesvirus, is an important cause of 
morbidity, and sometimes mortality, as a result of upper 
respiratory tract disease in cats. Clinical signs vary in 
severity, but include fever, depression, anorexia, ocular 
or nasal discharge, sneezing, conjunctival hyperemia 
and sometimes keratitis. Secondary bacterial infections 
are also common. Acutely infected cats and those that 
are latently infected but undergoing viral reactivation 
are the most important sources of infection.1 Other 
pathogens involved in feline upper respiratory tract 
infections include feline calicivirus (FCV), Bordetella 
bronchiseptica, Chlamydia felis and Mycoplasma felis and 
influenza virus.2–5 Herpetic disease and viral shedding 
are of particular importance within multi-cat environ-
ments, especially shelters, where in one study 53% of 
cats shed FHV-1 within 1 week of admission.2 Even in 
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home-based foster-care programs, clinically affected 
cats are more likely than healthy cats to shed FHV-1.6
Diagnosis of herpetic disease is often presumptive 
based on clinical signs. When a laboratory diagnosis is 
sought, PCR is typically preferred over traditional tech-
niques, such as virus isolation, owing to its higher sensi-
tivity and the rapidity with which results are available.7–10 
Two recent studies have evaluated sampling sites, 
showing that sampling multiple sites increases rate of 
PCR detection of FHV-1 DNA,11 and that there is no dif-
ference in detection rates for FHV-1 among sites, includ-
ing the tongue, oropharynx, conjunctiva and nares.12  
Interpretation of PCR results is, however, complicated 
by the fact that clinically normal cats shed FHV-1.8 
Quantification of FHV-1 correlated with severity of his-
topathologic changes in nasal epithelium from shelter 
cats with acute rhinitis, suggesting that quantitative PCR 
(qPCR) might be useful in differentiating between cats 
with latent or active FHV-1 infections.13 Conversely, 
another study of cats with signs of acute ocular and 
upper respiratory infections showed that FHV-1 qPCR 
results were not predictive of response to therapy with 
cidofovir ophthalmic drops.14 qPCR has been used to 
assess the efficacy of some antiviral drugs.15
Management of acute infectious upper respiratory 
disease in cats traditionally relies upon supportive care 
and treatment of secondary bacterial infections.1 The 
efficacy of some specific antiviral therapies has also been 
reported.16 Famciclovir is an oral prodrug of penciclovir, 
a nucleoside deoxyguanosine analogue with excellent 
efficacy against FHV-1. In cats experimentally infected 
with FHV-1, oral administration of famciclovir was asso-
ciated with significant reductions in clinical disease 
scores, histologic conjunctivitis scores, serum FHV-1 
antibody titers, serum globulin concentrations and con-
junctival FHV-1 DNA and RNA loads.17 Cats treated 
with famciclovir also showed increases in body weight.17 
Famciclovir administration has also been described in 
retrospective studies of cats with spontaneous disease 
believed to be due to FHV-1 infection.18,19 However, 
these were uncontrolled studies where FHV-1 infection 
was not confirmed and famciclovir has not been pro-
spectively evaluated in naturally infected FHV-1 cats. 
Few adverse effects have been associated with use of this 
drug in cats and it is regarded as generally safe.17,18,20
This study was designed to assess clinical and viro-
logic effects of famciclovir administration to cats with 
naturally acquired infectious upper respiratory disease. 
We hypothesized that using famciclovir would reduce 
clinical disease severity and duration of clinical signs in 
FHV-1-infected cats.
Materials and methods
Approval for this study was obtained from the 
Institutional Animal Care and Use Committee (#19021) 
and owners provided informed written consent regard-
ing their cat’s involvement. Cats with clinical signs of 
infectious upper respiratory disease of less than 30 days’ 
duration were prospectively recruited to this study from 
local rescue organizations that use home-based foster-
care programs in northern California, USA. Therefore, 
most cats in this study briefly transited through local 
shelters prior to study entry. More than one kitten from 
affected litters could be enrolled. Cats previously treated 
for upper respiratory tract infection were included if they 
had not responded to prior treatment and any treatment 
was of less than 7 days’ duration. Any concurrent health 
conditions were documented and cats excluded if these 
were severe enough to require hospitalization. Estimated 
age, breed, sex, neuter status and vaccination history 
were recorded on study entry. When known, presence of 
feline immunodeficiency virus (FIV) antibodies or feline 
leukemia virus (FeLV) antigens was also recorded.
At study entry (day 0), all cats were randomly 
assigned to one of two treatment groups. Randomization 
was performed using Microsoft Excel (2018) for the gen-
eration of random numbers; odd numbers were assigned 
to group D and even numbers to group DF.
Cats in group D received 5 mg/kg doxycycline mono-
hydrate suspension (5 mg/ml; Doxycycline for Oral 
Suspension USP, Lupin Pharmaceuticals) and placebo 
(lactose powder), each administered orally q12h. Cats in 
group DF received 5 mg/kg doxycycline suspension and 
90 mg/kg famciclovir, each administered orally q12h. 
The intent was to treat all cats for at least 7 days beyond 
the resolution of clinical signs. Doxycycline monohydrate 
suspension was reconstituted with water according to 
the manufacturer’s instructions. According to the pack-
age insert, this suspension was stable for 14 days at room 
temperature. Famciclovir was prepared by grinding 
commercially available tablets (Famciclovir 250 mg tab-
lets; Teva Pharmaceuticals Industries) into a fine powder 
that was then formulated into capsules containing 22.5, 
45, 90, 135 or 180 mg famciclovir. Lactose powder (pla-
cebo) was delivered using identical capsules filled to the 
same volume as those containing famciclovir. 
Owners of cats in both groups were asked to mix the 
contents of the capsule their cat was assigned with doxy-
cycline suspension in a small container and administer 
the total volume orally immediately after mixing. 
Owners were masked to capsule contents, with unmask-
ing performed at study end or if any adverse effects were 
reported. Owners of cats in group D were offered the 
opportunity to have their cats cross over into group DF if 
clinical signs persisted for more than 7 days.
At study entry and exit, each cat underwent a com-
plete physical examination performed by one of two 
investigators (LK or LJ), body weight and body condi-
tion score were recorded and an oculo-oropharyngeal 
swab was obtained using a sterile cotton-tipped 
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applicator (Fisherbrand polyester-tipped applicators; 
Fisher Scientific). One drop of 0.5% proparacaine hydro-
chloride ophthalmic solution was applied to both eyes. 
The swab was first rolled gently in the conjunctival sac 
of both eyes then in the oropharynx. Swabs were refrig-
erated for up to 48 h prior to submission to a commercial 
laboratory for assessment using qPCR specific for nucleic 
acids of FHV-1, FCV, C felis, B bronchiseptica, M felis and 
H7N2 influenza A virus (Feline Upper Respiratory Dis- 
ease RealPCR Panel, test code 2512; IDEXX Laboratories).
At study entry and exit, owners completed a ques-
tionnaire regarding severity, duration and history of 
clinical signs of upper respiratory tract disease (see the 
Appendix in the supplementary material). This ques-
tionnaire used a semiquantitative scoring system rang-
ing from 1 (mild) through 10 (severe) modified from one 
published by this group in related studies.21 Throughout 
the study, disease scores were assessed once daily by 
owners using a published scoring system.22 Owners 
were trained in disease scoring, including provision of 
a visual scale with examples of each score for ocular 
and nasal signs. After study exit, there was no ongoing 
follow-up of included cats.
For data analysis, an adequate response to therapy 
was defined as a reduction in owner-perceived sever-
ity of clinical signs by at least one grade (3 points on 
the scale). A priori power analysis conducted assum-
ing initial client scores in the moderate-to-severe range 
and treatment-related reduction to a mild-to-moderate 
score23 suggested that 25 cats per group would afford a 
power of 0.80 with probability of a type I error of 0.05 
(www.statisticalsolutions.net). However, this analysis 
did not consider differential rates of FHV-1 detection and 
likely underestimated the number of cats required to 
demonstrate significance.
Categorical responses were compared between treat-
ment groups at the onset and end of the study using 
Fisher’s exact test. Clinical scores were assessed for nor-
mality using D’Agostino and Pearson omnibus normal-
ity testing. For normally distributed data, Student’s t-test 
was used to assess differences between groups. Non-
parametric data were compared using the Mann Whitney 
U-test. Prevalence of positive vs negative qPCR results 
for upper respiratory pathogens was compared between 
each treatment group at each time point using Fisher’s 
exact test. The number of pathogens detected on PCR 
was correlated with day 1 clinical scores and number of 
days in treatment by use of linear regression. Statistical 
analyses were performed using a commercially available 
software package (GraphPad Prism version 5.0f) and sig-
nificance was set at P <0.05.
Results
A total of 32 cats were entered into the study. However, 
five were subsequently excluded from data analysis 
owing to incomplete data (one cat from group DF) or 
failure to return for clinical assessment (three cats from 
group D and 1 cat from group DF). One cat from group 
D died 4 days after study entry despite resolution of clin-
ical signs. The cause of death was unknown and a nec-
ropsy was not performed. Two cats in group D failed to 
show a response to therapy within 7 days, group assign-
ment was unmasked, and they were moved into group 
DF. Their data were considered separately to those of the 
other 24 cats. The remaining 24 cats were randomized 
equally into the two treatment groups. Enrolment was 
discontinued early when interim analysis did not reveal 
significant differences in response to therapy between 
treatment groups.
Considering all cats jointly, 12/24 (50%) were intact 
females, 8/24 (33%) were intact males, 3/24 (13%) were 
castrated males and 1/24 (4%) was a spayed female. The 
majority (96%) were domestic shorthair (n = 21), medi-
umhair (n = 1) or longhair (n = 1) cats; the remaining cat 
was a Himalayan cross. At study entry, median (range) 
age for all cats was 1.5 (1–6) months, body weight was 
0.7 (0.2–2.3) kg and body condition score was 4/9 (3/9–
5/9). No significant differences in demographic data 
were detected between cats assigned to group D or DF 
(Table 1). Antibodies to FIV were not detected in the five 
cats tested and FeLV antigens were not detected in the 11 
cats tested. The majority of cats (n = 16/24; 67%) had 
been vaccinated subcutaneously using a modified live 
vaccine against FHV-1, FCV and feline parvovirus at a 
median (range) time of 7 (1–31) days prior to study entry.
Five cats had received orally administered doxycy-
cline at an unknown dose for 24 h prior to study entry; 
these cats were assigned to group D (n = 3) or group DF 
(n = 2). Three cats had received oxytetracycline–poly-
myxin B ophthalmic ointment for 24 h prior to study 
entry; these cats were assigned to group D (n = 2) or 
group DF (n = 1). One cat had received polymyxin B, 
bacitracin and neomycin ophthalmic ointment for 24 h 
prior to study entry; this cat was assigned to group D.
Common reasons for presentation included sneezing 
(n = 24/24; 100%) and ocular (n = 23/24; 96%) or nasal 
(n = 22/24; 92%) discharge. Other reasons included hyp-
orexia (n = 1), lethargy (n = 3) or corneal ulceration 
(n = 1). No cat presented for poor response to prior treat-
ment. Information on disease duration was available for 
16 cats, and the median (range) disease duration prior to 
study entry was 7 (1–24) days, with no significant differ-
ence detected between group D and group DF (Table 1). 
Using the 10-point scale provided, median (range) 
owner-rated disease severity score at study entry for the 
24 included cats was 7 (1–9) for ocular discharge, 6 (1–10) 
for sneezing, 6.5 (1–10) for nasal discharge and 4 (1–9) for 
difficulty or noisy breathing. No significant differences 
were detected between disease severity scores at study 
entry for cats in group D or group DF (Table 1).
4 Journal of Feline Medicine and Surgery 
Median (range) study period for included cats did not 
significantly differ for cats in group DF (14 [11–21] days) 
or those in group D (19.5 [4–21] days; P = 0.92). According 
to owner-completed disease score sheets, cats demon-
strated clinical signs for a median (range) of 11.5 (3–21) 
days in group DF and 11 (3–21) days in group D (P = 0.75). 
Using the 10-point scale provided, median (range) 
owner-rated disease severity score for all cats at study 
exit was 1 (1–3) for ocular discharge, 1 (1–1) for sneezing, 
1 (1–1) for nasal discharge and 1 (1–1) for difficulty or 
noisy breathing in group D; and was 1 (1–2) for ocular 
discharge, 1 (1–4) for sneezing, 1 (1–1) for nasal discharge 
and 1 (1–3) for difficulty or noisy breathing in group DF. 
Median (range) total disease score at the end of the study 
did not differ between cats in group D (1 [1–1]) and those 
in group DF (1 [1–3]) (Figure 1; P = 0.08).
At study exit, median (range) body weight for all cats 
was 1 (0.5–2.8) kg with no significant difference detected 
between treatment groups (P = 0.40; Table 1). Likewise, 
median (range) body weight gain did not significantly 
differ between cats in group D (0.38 [0.20–0.55] kg) and 
those in group DF (0.32 [0.24–1.12] kg; P = 0.75).
The frequency with which known respiratory patho-
gens were detected using qPCR did not significantly 
differ for cats from each treatment group (Table 1). 
Considering all cats collectively, pathogens most com-
monly detected in oculo-oropharyngeal swabs at study 
entry were FCV (13/24 cats; 54%), M felis (n = 8/24; 
33%), FHV-1 (n = 7/24; 29%), C felis (n = 7/24; 29%) and 
B bronchiseptica (n = 3/24; 12%). Influenza virus was not 
detected in any cat. Combinations of infectious agents 
detected are shown in Table 2. The median (range) num-
ber of organisms detected per cat was 1 (0–4); 45.8% of 
cats had more than one infectious agent detected.
In the seven cats in which FHV-1 was detected at 
study entry, median (range) calculated number of viral 
copies was 1433 (0.9–8168) thousand per swab. At study 
Table 1 Summary data for 24 cats with spontaneous acute infectious upper respiratory disease receiving 5 mg/kg 
doxycycline suspension and 90 mg/kg famciclovir administered PO q12h (group DF; n = 12) or 5 mg/kg doxycycline 
suspension and placebo (lactose powder) administered PO q12h (group D; n = 12)
Group DF (n = 12) Group D (n = 12) P value
Median (range) age at study entry (months) 1.6 (1–5) 1.5 (1–6) 0.54
Median (range) body weight at study entry (kg) 0.65 (0.22–1.36) 0.70 (0.21–2.33) 0.89
Sex (male/female) 3/9 8/4 0.10
Median (range) body temperature at study entry (°F/ °C) 100.7 (98–103.3)/38.2 
(36.7–39.6)
101.4 (98.4–103.2)/38.6 
(36.9–39.6)
0.47
Median (range) duration of signs prior  
to study entry (days)
7 (1–24) 7 (4–21) 0.91
Median (range) clinical disease score at entry 11.5 (8–14) 11 (7–14) 0.78
Number of cats with positive qPCR results at study entry  
 Feline herpesvirus type 1 4/12 3/12 1.0
 Chlamydia felis 2/12 5/12 0.37
 Feline calicivirus 7/12 6/12 1.0
 Bordetella bronchiseptica 2/12 1/12 1.0
 Mycoplasma felis 5/12 3/12 0.67
 Influenza virus 0/12 0/12 1.0
Median (range) number of days from study entry until 
lowest clinical disease score
11.5 (3–21) 11 (3–21) 0.75
Median (range) body weight at study exit 0.97 (0.46–1.87) 1.08 (0.57–2.77) 0.40
qPCR = quantitative PCR
Figure 1 Comparison between median total clinical disease 
scores at study entry, day 7 and study end in 24 cats with 
spontaneous acute infectious upper respiratory disease 
receiving 5 mg/kg doxycycline suspension and 90 mg/kg 
famciclovir PO q12h (group DF; n = 12) or 5 mg/kg doxycycline 
suspension and placebo (lactose powder) each administered 
PO q12h (Group D; n = 12). No difference was detected 
between groups at study entry, day 7 or study end (P > 0.05)
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exit, FHV-1 DNA was detected in swabs from 2/24 (8%) 
cats: one from group DF in which calculated viral copy 
number decreased from 2761 thousand per swab at entry 
to 0.1 thousand per swab at exit; and one from group D 
in which calculated viral copy decreased from 2323 
thousand per swab at entry to 0.3 thousand per swab at 
exit. At study exit, FCV RNA was detected in two cats 
negative at study entry and M felis DNA in two cats neg-
ative at study entry. There was no correlation between 
number of pathogens isolated and day 1 clinical disease 
score (Figure 2; P = 0.78) or number of days of treatment 
until clinical resolution of signs (P = 0.75) or total num-
ber of days of treatment (Figure 3; P = 0.68).
Two cats crossed over from group D to group DF owing 
to poor response to 7 days of therapy. Both were 6-week-
old domestic shorthair cats – one female intact and one 
male castrated. Oculo-oropharyngeal swabs collected 
from these two cats contained nucleic acids of FCV and M 
felis for one cat and FCV only for the other. Clinical disease 
scores by day for these two cats are presented in Figure 4.
Discussion
The present study did not identify significant differ-
ences in outcome when cats with clinical signs of 
Table 2 Combinations of infectious agent nucleic acids detected by quantitative PCR (qPCR) assessment of oculo-
oropharyngeal swabs collected at study entry from 24 cats with spontaneous acute infectious upper respiratory disease
Infectious agents detected Number of 
cats
Median (range) 
clinical disease 
score at entry
Median (range) number of 
days from study entry to 
lowest clinical disease score
FCV 6 5 (2–8) 12 (3–21)
Chlamydia felis 3 7 (7–7) 14 (11–21)
FHV-1 2*† 4 (3–4) 10 (8–11)
FHV-1 and FCV 2*† 6 (6–6) 9 (6–12)
C felis and Mycoplasma felis 2 6 (4–8) 6 (6–6)
FCV, C felis, Bordetella bronchiseptica, M felis 2 8 (7–9) 11 (11–11)
FHV-1 and M felis 1* 8 21
FCV and C felis 1 5 18
FHV-1, FCV, M felis 1* 6 18
FCV, C felis, M felis 1 6 3
FHV-1, FCV, B bronchiseptica, M felis 1* 8 11
No agents detected 2 7 (7–7) 6 (3–8)
Total 24  
*Cats positive for FHV-1 on qPCR treated with doxycycline and famciclovir
†Cats positive for FHV-1 on qPCR treated with doxycycline
FCV = feline calicivirus; FHV-1 = feline herpesvirus type 1
Figure 2 Clinical disease score and number of pathogens 
detected in an oculo-oropharyngeal swab from 24 cats with 
spontaneous acute infectious upper respiratory disease at 
study entry
Figure 3 Duration of treatment and number of pathogens 
detected in an oculo-oropharyngeal swab at study entry from 
24 cats with spontaneous acute infectious upper respiratory 
disease
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spontaneous infectious upper respiratory disease were 
treated with doxycycline and famciclovir or with doxy-
cycline and placebo. Because we considered it unethical 
to have an untreated group, our data might reflect the 
potentially large proportion of young cats with infec-
tious respiratory disease that improve quickly regard-
less of therapy.24
Famciclovir has been found to be effective for treatment 
of cats following experimental inoculation with FHV-1.17 
In that study, famciclovir-treated cats had lower disease 
scores and higher percentage changes in weight than cats 
not receiving famciclovir.17 The difference in findings in 
the present study, where cats had naturally acquired, acute 
infectious upper respiratory disease, could be due to detec-
tion of more than one infectious agent in many cats, lower 
prevalence of FHV-1 detection in these cats, or both. 
Interestingly, two cats negative for FHV-1 DNA did not 
respond to doxycycline alone, but did improve rapidly 
after starting famciclovir. This could reflect false-negative 
qPCR results for FHV-1 or that these cats required more 
time to improve rather than change in therapy.
In a retrospective study of cats treated with famciclo-
vir for ocular, respiratory or dermatologic disease con-
sistent with FHV-1 infection, cats receiving famciclovir 
at 90 mg/kg PO q8h had a shorter median time to 
improvement and greater magnitude of improvement 
than cats receiving 40 mg/kg PO q8h.21 However, given 
that a pharmacokinetic study showed that administra-
tion of oral famciclovir at a dose of 40 or 90 mg/kg in 
healthy cats resulted in similar maximum concentrations 
and time to maximum concentrations, a lower dose of 
famciclovir could have been considered in the present 
study.25 In the retrospective study of cats treated with 
famciclovir, cats had clinical signs for a longer period 
before starting famciclovir (median 40 days)21 than did 
cats in the present study (median 7 days). This suggests 
famciclovir might be more likely to benefit cats with 
more chronic or recurrent clinical syndromes. Prospective 
evaluation of famciclovir administration to cats with 
more chronic clinical signs might better elucidate its effi-
cacy in such cases.
Although cats entered into the present study repre-
sented a clinically relevant population (ie, young cats 
presenting with spontaneous signs of acute infectious 
upper respiratory disease), FHV-1 DNA was detected 
using qPCR performed on an oculo-oropharyngeal sam-
ple in only 29% of cats. Although PCR is more sensitive 
than other tests for FHV-1, such as indirect immunofluo-
rescence and virus isolation,9 false-negative tests could 
have contributed to decreased prevalence in our study 
population.11 Conversely, several PCR assays detect vac-
cine virus and cannot discriminate it from wild-type 
FHV-1 in cats.8 This might be relevant in the present 
study because most cats were vaccinated a median of 7 
days before study entry, although this is also affected by 
vaccine type. In one vaccine challenge study, kittens 
receiving a modified live vaccine against FHV-1 did not 
have FHV-1 DNA detected on PCR, whereas some kit-
tens vaccinated using a modified live intranasal vaccine 
against FHV-1 did.26 In another study conducted in 
home-based foster-care programs, there was no differ-
ence in detection of FHV-1 DNA between cats that had 
Figure 4 Total clinical disease score by day for two cats that crossed over from group D to group DF on day 8 (cat 1) or day 7 
(cat 2). Arrows indicate the days on which each cat crossed over
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been recently vaccinated and those that had not.6 The 
effect of false-positive qPCR results for FHV-1 in the pre-
sent study is unknown.
A previous study evaluated upper respiratory tract 
pathogen prevalence in cats from four different environ-
ments.6 The prevalence with which infectious organism 
nucleic acids were detected in cats with clinical signs in 
home-based foster programs was similar to that pre-
sented here for FCV (42% vs 54% in the present study), 
FHV-1 (23% vs 29%), C felis (24% vs 29%) and B bron-
chiseptica (18% vs 12%). However, the proportion of cats 
from which M felis DNA was detected was notably lower 
in our population (33%) than the other study (59%).6 It is 
worth noting that qPCR failed to detect nucleic acids 
from any tested pathogen in swabs obtained from the 
two cats with the highest clinical disease scores at study 
entry. Given that their clinical signs were compatible 
with acute infectious upper respiratory disease, it is pos-
sible that this reflects a falsely negative qPCR result or 
that these cats were infected with an organism not 
detected by this assay. Because time of study entry pre-
ceded the time at which retroviral testing was routinely 
performed by home-based foster care organizations in 
this study, retroviral status was unknown for some cats 
evaluated. As a result, it was not possible to determine 
the impact of retroviral status on the prevalence of detec-
tion of infectious organism nucleic acids or response to 
treatment with famciclovir.
Conclusions
This study in cats with acute infectious upper respira-
tory disease revealed no significant difference in 
response to therapy with doxycycline alone vs doxycy-
cline with famciclovir, with cats in both groups improv-
ing rapidly. However, FHV-1 DNA was detected 
relatively uncommonly in this study and clinical trials 
focused on FHV-1-infected cats are warranted to better 
evaluate effects of famciclovir. In addition, clinical trials 
focusing on cats with more chronic FHV-1 infections are 
warranted.
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